Pseudophosphorylation of tau protein alters its ability for self‐aggregation

Filamentous tau protein deposits are a pathological hallmark of a group of neurodegenerative disorders (tauopathies). Tau protein in these aggregates is highly phosphorylated at different phosphorylation sites. Although tau filaments can be formed by heparin‐induced aggregation of unphosphorylated recombinant tau, it is not known how tau phosphorylation modulates aggregation behaviour. Analysis of the effect of tau phosphorylation at defined single or multiple sites is hampered by the low specificity of protein kinases and the highly dynamic turnover of phosphorylation in vivo. To overcome this problem we employed site‐directed mutagenesis to convert serine and threonine to aspartic acid or glutamic acid, which introduce a negative charge and conformational change that mimic phosphorylation. We tested 14 different mutated tau proteins for their propensity for self‐aggregation and formation of tau filaments. Tau aggregation was monitored with thioflavin S fluorescence in the presence of different inducers such as heparin, Al3+, Fe2+ and Fe3+. We found that mutations in the N‐terminal portion up to amino acid 208 mainly suppress tau aggregation, whereas mutations in the C‐terminal region mainly lead to an enhanced aggregation. Mutations in the middle portion of tau showed a mixed picture of suppression and enhancement of aggregation. A single amino acid change Ser422Glu has aggregation‐favouring properties with all four inducers.

[1]  T. Butz,et al.  Quantitative microanalysis of perineuronal nets in brain tissue , 2003 .

[2]  Wolfgang Härtig,et al.  Reversible Paired Helical Filament-Like Phosphorylation of Tau Is an Adaptive Process Associated with Neuronal Plasticity in Hibernating Animals , 2003, The Journal of Neuroscience.

[3]  Michel Goedert,et al.  Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-β structure , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Shin,et al.  A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated τ of Alzheimer’s disease , 2003, Brain Research.

[5]  T. Fath,et al.  Tau-Mediated Cytotoxicity in a Pseudohyperphosphorylation Model of Alzheimer's Disease , 2002, The Journal of Neuroscience.

[6]  Hirotaka Yoshida,et al.  Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein , 2002, The Journal of Neuroscience.

[7]  Ernest Beutler,et al.  Brain Iron Metabolism and Neurodegenerative Disorders , 2002, Developmental Neuroscience.

[8]  A. Delacourte,et al.  Abnormal Tau phosphorylation of the Alzheimer‐type also occurs during mitosis , 2002, Journal of neurochemistry.

[9]  Hironobu Naiki,et al.  Iron (III) induces aggregation of hyperphosphorylated τ and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease , 2002 .

[10]  J. Ávila,et al.  Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases , 2002, Peptides.

[11]  M. Pool,et al.  Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. , 2001, The Biochemical journal.

[12]  V. Muñoz,et al.  In vitro assembly of tau protein: mapping the regions involved in filament formation. , 2001, Biochemistry.

[13]  R. Crowther,et al.  The natural osmolyte trimethylamine N‐oxide (TMAO) restores the ability of mutant tau to promote microtubule assembly , 2000, FEBS letters.

[14]  J. Kuret,et al.  C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. , 2000, Journal of cell science.

[15]  T. Fath,et al.  Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins. , 2000, Biochemistry.

[16]  E. Mandelkow,et al.  Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Shin,et al.  Interaction of aluminum with PHFtau in Alzheimer's disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method. , 1999, The American journal of pathology.

[18]  Wei Li,et al.  Heparin-induced Conformational Change in Microtubule-associated Protein Tau as Detected by Chemical Cross-linking and Phosphopeptide Mapping* , 1999, The Journal of Biological Chemistry.

[19]  E. Mandelkow,et al.  Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. , 1999, Biochemistry.

[20]  E. Mandelkow,et al.  A nucleated assembly mechanism of Alzheimer paired helical filaments. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Wei Li,et al.  Phosphorylation sensitizes microtubule-associated protein τ to Al3+-induced aggregation , 1998, Neurochemical Research.

[22]  M. Goedert,et al.  Tau protein pathology in neurodegenerative diseases , 1998, Trends in Neurosciences.

[23]  E. Mandelkow,et al.  Mitotic phosphorylation of tau protein in neuronal cell lines resembles phosphorylation in Alzheimer's disease. , 1998, European journal of cell biology.

[24]  M. Herman,et al.  Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease. , 1998, Neurotoxicology.

[25]  Masato Hasegawa,et al.  Alzheimer-like Changes in Microtubule-associated Protein Tau Induced by Sulfated Glycosaminoglycans , 1997, The Journal of Biological Chemistry.

[26]  J. Ávila,et al.  Role of glycosaminoglycans in determining the helicity of paired helical filaments. , 1997, The American journal of pathology.

[27]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Shin Interaction of aluminum with paired helical filament tau is involved in neurofibrillary pathology of Alzheimer's disease. , 1997, Gerontology.

[29]  J. Connor,et al.  Regional distribution of iron, transferrin, ferritin, and oxidatively-modified proteins in young and aged Fischer 344 rat brains , 1997, Neuroscience.

[30]  R. Brandt,et al.  Conversion of Serine to Aspartate Imitates Phosphorylation-induced Changes in the Structure and Function of Microtubule-associated Protein Tau* , 1997, The Journal of Biological Chemistry.

[31]  R. Crowther,et al.  Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans , 1996, Nature.

[32]  R. Crowther,et al.  Characterization of mAb AP422, a novel phosphorylation‐dependent monoclonal antibody against tau protein , 1996 .

[33]  C. Bergeron,et al.  Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories , 1996, Neurology.

[34]  K. Titani,et al.  Proline-directed and Non-proline-directed Phosphorylation of PHF-tau (*) , 1995, The Journal of Biological Chemistry.

[35]  J. Trojanowski,et al.  Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[36]  C. W. Scott,et al.  Aggregation of tau protein by aluminum , 1993, Brain Research.

[37]  J. H. Wang,et al.  Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. , 1993, The Journal of biological chemistry.

[38]  Y. Ihara,et al.  τ in Paired Helical Filaments Is Functionally Distinct from Fetal τ: Assembly Incompetence of Paired Helical Filament‐τ , 1993 .

[39]  John Q. Trojanowski,et al.  Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule binding , 1993, Neuron.

[40]  R. Brandt,et al.  Functional organization of microtubule-associated protein tau. Identification of regions which affect microtubule growth, nucleation, and bundle formation in vitro. , 1993, The Journal of biological chemistry.

[41]  G. Sarkar,et al.  The "megaprimer" method of site-directed mutagenesis. , 1990, BioTechniques.

[42]  A. Frankfurter,et al.  The distribution of tau in the mammalian central nervous system , 1985, The Journal of cell biology.

[43]  M. Kirschner,et al.  Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. , 1977, Journal of molecular biology.

[44]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[45]  INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .

[46]  Hironobu Naiki,et al.  Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. , 2002, Journal of neurochemistry.

[47]  W R Markesbery,et al.  Oxidative stress hypothesis in Alzheimer's disease. , 1997, Free radical biology & medicine.

[48]  Y. Ihara,et al.  Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau. , 1993, Journal of neurochemistry.